Lifecore Biomedical
LFCR
77 hedge funds and large institutions have $203M invested in Lifecore Biomedical in 2024 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 29 increasing their positions, 19 reducing their positions, and 19 closing their positions.
268% more call options, than puts
Call options by funds: $375K | Put options by funds: $102K
73% more capital invested
Capital invested by funds: $117M → $203M (+$85.5M)
53% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 19
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
0.37% more ownership
Funds ownership: 67.02% → 67.39% (+0.37%)
6% less funds holding
Funds holding: 82 → 77 (-5)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPAM
Legion Partners Asset Management
Los Angeles,
California
|
+$9.35M |
| 2 |
GRIM
Greenhaven Road Investment Management
Greenwich,
Connecticut
|
+$8.86M |
| 3 |
3C
325 Capital
New York
|
+$5.06M |
| 4 |
Invesco
Atlanta,
Georgia
|
+$3.55M |
| 5 |
DA
DCF Advisers
Greenwich,
Connecticut
|
+$1.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.85M |
| 2 |
WC
Wynnefield Capital
New York
|
-$1.38M |
| 3 |
2C
272 Capital
Dallas,
Texas
|
-$707K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$639K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$431K |
LFCR Hedge Fund Activity: Q4 2024 in Review
77 of the 7,607 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q4 2024, worth a combined $203M — up 73% from $117M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of LFCR and 14 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 29 added.
The largest buyer was Legion Partners Asset Management, adding an estimated $9.35M. The largest seller was Deutsche Bank, cutting an estimated $1.85M.
- 77 institutional investors held Lifecore Biomedical (LFCR) as of Q4 2024, down from 82 in Q3 2024.
- Funds reported $203M of Lifecore Biomedical stock for Q4 2024, up 73% quarter-over-quarter.
- 14 funds opened new Lifecore Biomedical positions in Q4 2024 and 19 closed out, a net change of -5 holders.
- The largest Lifecore Biomedical buyer in Q4 2024 was Legion Partners Asset Management, an estimated $9.35M added.
- The largest Lifecore Biomedical seller in Q4 2024 was Deutsche Bank, an estimated $1.85M sold.
Based on aggregated 13F filings for Q4 2024.